Polycystic Kidney Disease - Pipeline Review, H1 2018

  • ID: 4529333
  • Report
  • 108 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • DiscoveryBiomed Inc
  • Genzyme Corp
  • Ipsen SA
  • ManRos Therapeutics
  • NovaTarg Therapeutics Inc
  • MORE
Polycystic Kidney Disease - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2018, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights:

This latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 4, 10 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • DiscoveryBiomed Inc
  • Genzyme Corp
  • Ipsen SA
  • ManRos Therapeutics
  • NovaTarg Therapeutics Inc
  • MORE
Introduction

Report Coverage

Polycystic Kidney Disease - Overview

Polycystic Kidney Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Kidney Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Kidney Disease - Companies Involved in Therapeutics Development

Angion Biomedica Corp

Celgene Corp

Conatus Pharmaceuticals Inc

DiscoveryBiomed Inc

Endocyte Inc

Genzyme Corp

IC-MedTech Inc

Ipsen SA

Kadmon Corp LLC

ManRos Therapeutics

Metabolic Solutions Development Company LLC

Mironid Ltd

NovaTarg Therapeutics Inc

Otsuka Holdings Co Ltd

Q BioMed Inc

Reata Pharmaceuticals Inc

Regulus Therapeutics Inc

Polycystic Kidney Disease - Drug Profiles

(sodium ascorbate + menadione sodium bisulfite) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bardoxolone methyl - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBM-43H11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Cystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-0371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibiglustat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-8050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lixivaptan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

menadione sodium bisulfite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSDC-0160 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxypurinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrimethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGLS-4326 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ricolinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PDE4 for Polycystic Kidney Disease and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit STAT3 for Oncology and Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesevatinib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolvaptan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycystic Kidney Disease - Dormant Projects

Polycystic Kidney Disease - Discontinued Products

Polycystic Kidney Disease - Product Development Milestones

Featured News & Press Releases

Feb 27, 2018: Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials

Dec 19, 2017: Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Nov 13, 2017: Kadmon Initiates Phase 2 Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease

Nov 09, 2017: FDA Accepts Otsuka's Resubmission To Support A Regulatory Review Of Tolvaptan In The Treatment Of ADPKD

Nov 06, 2017: Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 01, 2017: Palladio Biosciences Announces Presentations of New Data for Lixivaptan and Polycystic Kidney Disease during the American Society of Nephrology 2017 Annual Meeting

Oct 27, 2017: Otsuka to Host Web Briefing on Tolvaptan Phase 3 Trial Results in Polycystic Kidney Disease

Oct 04, 2017: Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Jun 12, 2017: Palladio Biosciences Announces Appointment of Frank C. Condella, Jr. to Board of Directors

Jun 12, 2017: Regulus Announces Pipeline Update and Advancement on RGLS-

May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S

May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S.

Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan

Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD

Jan 30, 2017: Mironid announces additional non-dilutive funding through an Early Stage Award from Innovate UK’s Biomedical Catalyst

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Table 1: Number of Products under Development for Polycystic Kidney Disease, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Universities/Institutes, H1 2018

Table 5: Products under Development by Companies, H1 2018

Table 6: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 7: Products under Development by Universities/Institutes, H1 2018

Table 8: Number of Products by Stage and Target, H1 2018

Table 9: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 10: Number of Products by Stage and Mechanism of Action, H1 2018

Table 11: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 12: Number of Products by Stage and Route of Administration, H1 2018

Table 13: Number of Products by Stage and Molecule Type, H1 2018

Table 14: Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H1 2018

Table 15: Polycystic Kidney Disease - Pipeline by Celgene Corp, H1 2018

Table 16: Polycystic Kidney Disease - Pipeline by Conatus Pharmaceuticals Inc, H1 2018

Table 17: Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H1 2018

Table 18: Polycystic Kidney Disease - Pipeline by Endocyte Inc, H1 2018

Table 19: Polycystic Kidney Disease - Pipeline by Genzyme Corp, H1 2018

Table 20: Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H1 2018

Table 21: Polycystic Kidney Disease - Pipeline by Ipsen SA, H1 2018

Table 22: Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H1 2018

Table 23: Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H1 2018

Table 24: Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company LLC, H1 2018

Table 25: Polycystic Kidney Disease - Pipeline by Mironid Ltd, H1 2018

Table 26: Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H1 2018

Table 27: Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co Ltd, H1 2018

Table 28: Polycystic Kidney Disease - Pipeline by Q BioMed Inc, H1 2018

Table 29: Polycystic Kidney Disease - Pipeline by Reata Pharmaceuticals Inc, H1 2018

Table 30: Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H1 2018

Table 31: Polycystic Kidney Disease - Dormant Projects, H1 2018

Table 32: Polycystic Kidney Disease - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Polycystic Kidney Disease, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Top 10 Targets, H1 2018

Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Routes of Administration, H1 2018

Figure 9: Number of Products by Top 10 Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Angion Biomedica Corp
  • Celgene Corp
  • Conatus Pharmaceuticals Inc
  • DiscoveryBiomed Inc
  • Endocyte Inc
  • Genzyme Corp
  • IC-MedTech Inc
  • Ipsen SA
  • Kadmon Corp LLC
  • ManRos Therapeutics
  • Metabolic Solutions Development Company LLC
  • Mironid Ltd
  • NovaTarg Therapeutics Inc
  • Otsuka Holdings Co Ltd
  • Q BioMed Inc
  • Reata Pharmaceuticals Inc
  • Regulus Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll